STAT

OCTOBER 23, 2024

Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA.

Compounding 263

Compounding Compounding Pharmacies Biosimilars Documentation 263

STAT

AUGUST 10, 2023

In late May, the Food and Drug Administration said it received a “few” adverse event reports concerning compounded versions of the injectable medicines, which both contain the same active ingredient, known as semaglutide. The notice raised an important question: To what extent should the public be concerned?

Compounding 246

Compounding Diabetes 246

STAT

OCTOBER 11, 2024

The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, from its shortage list, and, for the time being, would not pursue regulatory action against certain compounding pharmacies making copies of the drugs. 

Compounding Pharmacies 350

Compounding Pharmacies Compounding Diabetes 350

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. The agency then made a sudden about-face , saying it would reconsider its decision and allow compounders to continue for the meantime.

Compounding Pharmacies 358

Compounding Pharmacies Compounding Diabetes 358

STAT

SEPTEMBER 20, 2023

… As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequently used for combating obesity, STAT writes.

Compounding 255

Compounding Compounding Pharmacies Diabetes 255

STAT

FEBRUARY 26, 2024

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Diabetes 362

Diabetes Compounding Drug Development 362

STAT

OCTOBER 8, 2024

… A trade group representing large compounding pharmacies has sued the U.S. Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us.

Compounding 262

Compounding Compounding Pharmacies Vaccines Immunity 262

STAT

AUGUST 2, 2024

In the face of ongoing shortages of the obesity and diabetes medications known as GLP-1s, patients have resorted to a wide array of sources for the drugs, including medical spas and telehealth sites that prescribe compounded versions of the drugs.

Online Pharmacies 360

Online Pharmacies Labelling Compounding Diabetes 360

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. The agency then made a sudden about-face , saying it would reconsider its decision and allow compounders to continue for the meantime.

Compounding Pharmacies 285

Compounding Pharmacies Compounding Diabetes 285

STAT

NOVEMBER 18, 2022

The first therapy that delays the onset of type 1 diabetes received approval from the U.S. million people have type 1 diabetes in the U.S., according to the American Diabetes Association, including 244,000 children and adolescents. Type 1 affects 8% of everyone with diabetes. Food and Drug Administration , CNN tells us.

Diabetes 246

Diabetes Biosimilars Documentation Compounding 246

BioPharma Dive

DECEMBER 2, 2024

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.

Compounding 122

Compounding Compounding Pharmacies Diabetes 122

STAT

OCTOBER 17, 2024

Dozens of companies have started to offer the wildly popular obesity and diabetes medications, meeting patients who are flooding online for prescriptions that could help them lose as much as 20% of their body weight.  In the last two years, telehealth has gone all in on GLP-1s.

Compounding 362

Compounding Diabetes 362

pharmaphorum

OCTOBER 14, 2024

Faced with lawsuit, FDA rethinks block on compounding pharmacies making Eli Lilly's diabetes and obesity drug tirzepatide

Compounding 110

Compounding Compounding Pharmacies Diabetes 110

STAT

OCTOBER 31, 2024

… All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available  on the U.S. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.

Compounding Pharmacies 271

Compounding Pharmacies Compounding Diabetes Packaging 271

pharmaphorum

OCTOBER 23, 2024

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely by these manufacturers.

Compounding 116

Compounding Compounding Pharmacies Diabetes 116

Express Pharma

JULY 28, 2024

Food and Drug Administration recently warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s weight-loss and diabetes drugs. The post US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug appeared first on Express Pharma.

Compounding 103

Compounding Diabetes 103

STAT

DECEMBER 20, 2024

The agency will give compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients. That should have prohibited compounders from continuing to make copies, because they can do so only when a treatment is on the shortage list.

Compounding 280

Compounding Diabetes 280

STAT

JUNE 20, 2024

We have adjusted our settings to accept postcards and telegrams… After taking legal action last year, Eli Lilly filed even more lawsuits against several spas, compounders and wellness centers over unapproved versions of tirzepatide, which is the active ingredient in Mounjaro and Zepbound,   STAT notes.

Diabetes 291

Diabetes Compounding Drug Pricing Drug Development 291

PharmaVoice

OCTOBER 21, 2024

After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.

Compounding 173

Compounding Diabetes 173

STAT

JUNE 20, 2023

are illegally selling compounded versions of its medicines. All three drugs are used to treat diabetes, although Wegovy was also approved by U.S. In the latest fracas over obesity drugs , Novo Nordisk filed lawsuits alleging several medical spas, wellness clinics, and weight loss clinics around the U.S.

Compounding 246

Compounding Diabetes 246

STAT

SEPTEMBER 22, 2023

The techs who were queried identified chemotherapies; ADHD medicines; three drugs for weight loss and diabetes — Mounjaro, Ozempic, and Wegovy — and local anesthetics such as lidocaine as the top drugs experiencing shortages. And 72% said shortages very significantly or significantly impact their workflow.

Department of Veterans Affairs 278

Department of Veterans Affairs Pharmacy Technician Compounding Pharmacies Compounding 278

STAT

JANUARY 25, 2024

last year after taking suspected fake versions of Novo Nordisk’s diabetes drug Ozempic , Reuters reports, citing data from America’s Poison Centers. One Ozempic and similar diabetes medicines have been increasingly used off label for weight loss. Food and Drug Administration to identify public health risks.

Labelling 270

Labelling Diabetes Compounding 270

STAT

OCTOBER 25, 2024

Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years. By law, that should have prohibited compounding pharmacies from making copies of the drug, as they are allowed to do so only when the treatment is on the shortage list.

Compounding 256

Compounding Compounding Pharmacies Diabetes Drug Development 256

Compounding Pharmacy of America

FEBRUARY 23, 2023

Many people need to address diabetes. So, how well does compounding diabetic medication address symptoms and one’s lifestyle? The post Supplements and Compounding Diabetic Medications appeared first on The Compounding Pharmacy of America.

Compounding 52

Compounding Diabetes Compounding Pharmacies 52

Express Pharma

JANUARY 2, 2025

The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in 2023 to $9.9

Diabetes 105

Diabetes Vaccines Compounding 105

Express Pharma

AUGUST 28, 2023

Queen’s University Belfast has designed a new 3D printed bandage which presents an innovative method of treatment to heal diabetic foot ulcers (DFUs). These scaffolds can release both a bulk and sustained release of antibiotic loaded molecules to treat diabetic ulcers.

Diabetes 98

Diabetes Dosage Compounding Hospitals 98

Pharmafile

JANUARY 20, 2023

Pharmaceutical company Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found in its popular type 2 diabetes drugs. The compound, known as nitrosamines or NTTP, often emerges from chemical reactions that can take place throughout the manufacturing process. read more

Compounding 52

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

Compounding Pharmacy of America

MARCH 29, 2024

An exploration of how proper diet, exercise, and a regiment of supplements combined with GLP-1 therapies can prevent and treat type 2 diabetes. The post The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment appeared first on The Compounding Pharmacy of America.

Diabetes 59

Diabetes Compounding Pharmacies Compounding 59

Pharmaceutical Technology

MARCH 26, 2024

for novel compounds targeting apelin receptors. Learn about the compound's potential in treating cardiovascular disease, diabetes, cancer, and more. Discover the groundbreaking patent by Sosei Group Corp.

Compounding 52

Compounding Diabetes 52

Compounding Pharmacy of America

DECEMBER 6, 2024

While many men experience occasional difficulties with sexual performance, persistent ED can be an early warning sign of serious underlying health issues such as cardiovascular disease, diabetes, or hormonal imbalances.

Compounding Pharmacies 98

Compounding Pharmacies Compounding Diabetes 98

Express Pharma

NOVEMBER 4, 2024

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month. regulations.

Compounding 105

Compounding Diabetes 105

Welltopia Pharmacy

FEBRUARY 27, 2024

Compounded Semaglutide: A Modern Approach to Medication Compounded Semaglutide is a sophisticated version of the widely recognized Semaglutide medication, designed to meet the specific health needs of individuals.

Compounding 40

Compounding Diabetes 40

Compounding Pharmacy of America

JULY 11, 2023

For those who are diabetic, there are vitamins, supplements, and compounding medications that can help you manage your condition. The post From A to Zinc: How Vitamins Help Manage Diabetes appeared first on The Compounding Pharmacy of America.

Diabetes 40

Diabetes Compounding Pharmacies Compounding 40

National Association of Boards of Pharmacy

DECEMBER 13, 2023

Injectable diabetes medications including semaglutide, namely Wegovy and Ozempic, have been in shortage since 2022 , limiting patient access to the drug across the nation. Simultaneously, compounding pharmacies have been overwhelmed with the production of semaglutide injections that are compounded copies of Ozempic and Wegovy.

Diabetes 56

Diabetes Compounding Pharmacies Compounding Online Pharmacies 56

Welltopia Pharmacy

OCTOBER 17, 2024

A GLP-1 compounding pharmacy offers patients a customized, often more affordable alternative. Glucagon-like peptide-1 (GLP-1) receptor agonists have become essential in managing type 2 diabetes and aiding in weight loss.

Compounding Pharmacies 40

Compounding Pharmacies Compounding Diabetes 40

pharmaphorum

DECEMBER 21, 2022

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The post Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2 appeared first on.

Diabetes 52

Diabetes Compounding 52

pharmaphorum

FEBRUARY 15, 2022

One in four of the world’s rivers are polluted with potentially toxic levels of pharma compounds, according to a new study.

Compounding 105

Compounding Pharmaceutical Manufacturing Diabetes 105